

Attorney Docket No. P63187US2  
Application No. 10/722,467

**Amendments to the claims:**

This listing of claims replaces all prior versions, and listings, of claims in the application.

**Listing of claims:**

Claims 1-11 (canceled).

12 (previously presented): Process for treating lameness caused by osteoarthritis, in a non-human animal suffering from osteoarthritis and not suffering from fractures, comprising the administration, to the non-human animal, of an effective amount of a bisphosphonic acid derivative selected from the group consisting of:

- 1-hydroxyethylidenebisphosphonic acid and its sodium salts;
- 2-pyrid-2-ylethylidenebisphosphonic acid and its sodium salts;
- phenoxymethylenebisphosphonic acid and its salts;
- thiomorpholinomethylenebisphosphonic acid and its salts;
- 4-chlorophenylthiomethylenebisphosphonic acid and its salts;
- 1-hydroxy-2-(3-pyridyl)ethylidenebisphosphonic acid and its sodium salts;
- 1-hydroxy-2-(2-imidazolyl)ethyl-1,1-bisphosphonic acid and its salts; and
- 2-hydroxyethylidene-2-(3-pyridyl)-1,1-bisphosphonic acid and its sodium salts.

Attorney Docket No. P63187US2  
Application No. 10/722,467

- 13 (previously presented): Process according to claim 12, for treating an animal belonging to the equidae family.
- 14 (previously presented): Process according to claim 12, for treating a horse.
- 15 (previously presented): Process according to claim 12, comprising the administration of 0.001 mg/kg to 100 mg/kg of body weight of the bisphosphonic acid derivative.
- 16 (previously presented): Process according to claim 12, for treating limps in horses, comprising the intravenous administration of 0.01 mg/kg/week to 1 mg/kg/week of tiludronic acid or one of its pharmaceutically acceptable salts.
- 17 (previously presented): Process according to claim 12, comprising the oral administration of the bisphosphonic acid derivative.
- 18 (previously presented): Process according to claim 12, comprising the parenteral administration of the bisphosphonic acid derivative.
- 19 (previously presented): Process according to claim 12, comprising the administration of the bisphosphonic acid derivative in the form of an implant.

Attorney Docket No. P63187US2  
Application No. 10/722,467

- 20 (previously presented): Process according to claim 12, in which the bisphosphonic acid derivative is 4-chlorophenylthiomethylenebisphosphonic acid.
- 21 (previously presented): Process for treating lameness caused by osteoarthritis, in a horse suffering from osteoarthritis and not suffering from fractures, comprising the administration, to the horse, of an effective amount of 4-chlorophenylthiomethylene-bisphosphonic acid or its sodium salt.
- 22 (new): Process for treating lameness caused by osteoarthritis, in a non-human animal suffering from osteoarthritis and not suffering from fractures, comprising the administration, to the non-human animal, of an effective amount of a bisphosphonic acid derivative selected from the group consisting of:
- 1-hydroxyethylidenebisphosphonic acid and its sodium salts;
  - 2-pyrid-2-ylethylidenebisphosphonic acid and its sodium salts;
  - phenoxymethylenebisphosphonic acid and its salts;
  - thiomorpholinomethylenebisphosphonic acid and its salts;
  - 4-chlorophenylthiomethylenebisphosphonic acid and its salts;
  - 1-hydroxy-2-(3-pyridyl)ethylidenebisphosphonic acid and its sodium salts;
  - 1-hydroxy-2-(2-imidazolyl)ethyl-1,1-bisphosphonic acid and its salts; and

Attorney Docket No. P63187US2  
Application No. 10/722,467

— 2-hydroxyethylidene-2-(3-pyridyl)-1,1-bisphosphonic acid and its sodium salts;  
without any increase in bone density being detectable by radiological examination following  
treatment.